Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial

Table 2 Summary of treatment-related adverse events

All events	No. of patients (%)
All events	Total	Grade 1–2	Grade 3–4
Alopecia	32 (68.1)	32 (68.1)	0 (0)
Reactive cutaneous capillary endothelial proliferation	28 (59.6)	28 (59.6)	0 (0)
Fatigue	26 (55.3)	25 (53.2)	1 (2.1)
Anemia	25 (53.2)	24 (51.1)	1 (2.1)
Muscle soreness	20 (42.6)	20 (42.6)	0 (0)
Limb numbness	20 (42.6)	19 (40.4)	1 (2.1)
Increased alanine transaminase	11 (23.4)	11 (23.4)	0 (0)
Constipation	8 (17.0)	8 (17.0)	0 (0)
Diarrhea	4 (8.5)	4 (8.5)	0 (0)
Immune-related hyperthyroidism	4 (8.5)	4 (8.5)	0 (0)
Leukopenia	3 (6.4)	3 (6.4)	0 (0)
Vomiting	2 (4.3)	2 (4.3)	0 (0)
Nausea	2 (4.3)	2 (4.3)	0 (0)
Immune-related hypothyroidism	2 (4.3)	2 (4.3)	0 (0)
Thrombocytopenia	2 (4.3)	2 (4.3)	0 (0)
Immune-related myocarditis	1 (2.1)	0 (0)	1 (2.1)
Cough	0 (0)	0 (0)	0 (0)
Immune-related pneumonia	0 (0)	0 (0)	0 (0)
Immune-related hepatitis	0 (0)	0 (0)	0 (0)
Immune-related nephritis	0 (0)	0 (0)	0 (0)

All adverse events were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0

ISSN: 1479-5876